The Medical Letter on Drugs and Therapeutics
Influenza Vaccine for 2014-2015
The full article is available to subscribers Subscriber Login   
Revised 11/5/2014: See Tables 1 and 2 for new age indication for FluBlok (now ≥18 years).

Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications.1

EFFECTIVENESS — The effectiveness of the seasonal vaccine in preventing influenza in healthy adults depends on the match between the vaccine and circulating strains. Vaccine effectiveness is highest (50-80% in young adults; lower in the elderly) when the match is close, but even when the match is poor, vaccination has been shown to reduce the risk of death from influenza.2 In addition, vaccination of children and adolescents can protect unvaccinated residents of the same community.3

Live vs. Inactivated – The intranasal live-attenuated influenza vaccine, FluMist Quadrivalent, is only recommended for healthy, non-pregnant persons 2-49 years old. It appears ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Influenza Vaccine for 2014-2015
Article code: 1453a
 Electronic, downloadable article - $25